Valiant Laboratories Limited has submitted the Exchange a copy of Scrutinizers report and Voting Results of Annual General Meeting held on September 25, 2025.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Laboratories held its 4th AGM on September 25, 2025 via video conferencing, where all 12 resolutions were passed with the required majority. Of the company's total 5.43 crore equity shares, about 76.89% (4.17 crore shares) were voted, with promoters (holding ~74.93% stake) participating on most items. Resolutions included adoption of FY25 audited financials, re-appointment of Managing Director Santosh Vora, ratification of cost auditor remuneration, appointment of M/s Mehta & Mehta as secretarial auditors, designation change and remuneration revisions for two directors, and five material related party transactions with Valiant Organics, Aarti Pharmalabs, and Alchemie Speciality Chemicals. For the five RPT resolutions, promoters abstained due to conflict of interest, so only public shareholders (about 1.93% of total shares) voted, with over 99.86% in favor in each case. All other resolutions received over 99.997% approval.
Smooth passage of all 12 resolutions, including multiple related party transactions with group companies, signals strong shareholder alignment with management and no governance flashpoints. The high promoter holding (~74.93%) ensures outcomes are largely predetermined, but even the limited public vote on RPTs showed overwhelming support, suggesting no material investor concerns at this stage.